12:00 AM
Jul 20, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onsolis regulatory update

FDA approved an NDA from BioDelivery Sciences for Onsolis (formerly BEMA fentanyl) to treat breakthrough cancer pain in opioid-tolerant adults. Because fentanyl is subject to misuse and abuse, the approval included a risk evaluation and...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >